• Important Safety Information  |  
• Site Map  |  
• CRESTOR Consumer Site

• E-mail page
• Print page
• Text size:   

As an adjunct to diet, CRESTOR^® (rosuvastatin calcium) is indicated to lower LDL-C, raise HDL-C, and is approved to slow the progression of atherosclerosis in adult patients as part of a treatment plan to lower cholesterol to goal.¹

Reduce LDL-C and raise HDL-C

CRESTOR is indicated along with diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia.¹

• Lower LDL-C and raise HDL-C with a low 10-mg dose of CRESTOR ¹
• In patients with type 2 diabetes, up to 94%^± achieved LDL-C goal of <100 mg/dL^§ with a starting dose of CRESTOR 10 mg^11,12,13
• Safety profile in line with other leading statins^{1, 9, 10}

^±In 3 titration trials of patients with type 2 diabetes treated with a starting dose of CRESTOR 10 mg.

In the ANDROMEDA trial (n=240), 94% reached LDL-C goal of <96.5 mg/dL at 8 weeks. There was a mean LDL-C reduction of 51% from baseline of 131 mg/dL. The primary end point was the percentage change from baseline in LDL-C after 16 weeks.¹¹

In the CORALL trial (n=130), 82% reached LDL-C goal of <100 mg/dL at 6 weeks. There was a mean LDL-C reduction of 46% from baseline of 163 mg/dL. The primary end point, the percentage change from baseline in ApoB/ApoA1 ratio after 6 weeks, was not significantly different between CRESTOR and atorvastatin. LDL-C goal achievement was another end point.¹²

In the URANUS trial (n=232), 65% reached LDL-C goal of <100 mg/dL at 4 weeks. There was a mean LDL-C reduction of 48% from baseline of 178 mg/dL. The primary end point was the percentage change from baseline in LDL-C after 16 weeks.¹³

^§According to the third report of the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) update, the LDL-C goal is <160 mg/dL for lower-risk patients, <130 mg/dL for moderate-risk patients, <130 mg/dL (optional goal of <100 mg/dL) for moderately at-risk patients, <100 mg/dL for at-risk patients, and an optional goal of <70 mg/dL for very at-risk patients.^14,15

Slow the progression of atherosclerosis

As an adjunct to diet, CRESTOR is approved to slow the progression of atherosclerosis in at-risk patients as part of a treatment strategy to lower Total-C and LDL-C to target levels.¹

The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined. Long-term outcomes studies are currently under way.¹

Atherosclerosis is a common, progressive vascular disease.^15,16

Atherosclerotic plaques can progress significantly before they are detected.^15,16

Is your statin of choice indicated to slow the progression of atherosclerosis?

^‖Statin combination = a fixed-dose combination of 2 agents.
^¶Multiple generic formulations are widely available.

Unlike Lipitor and simvastatin, CRESTOR has not been shown to reduce cardiovascular morbidity and mortalitiy; long-term outcome studies are currently under way.

Lescol and Lescol XL are registered trademarks of Novartis Pharmaceuticals Corporation.
Mevacor is a registered trademark of Merck & Co., Inc.
Pravachol is a registered trademark of Bristol-Myers Squibb Company.
Lipitor is a registered trademark of Pfizer Inc.
Zocor is a registered trademark of Merck & Co., Inc.
Vytorin is a registered trademark of MSP Singapore Company, LLC.

Help your at-risk patients understand atherosclerosis

There is an opportunity to raise awareness about atherosclerosis. The ongoing dialogue you have with your at-risk patients builds greater understanding about this prevalent health condition. By educating your patients about atherosclerosis, we can

• Raise awareness about the disease
• Communicate the importance of cholesterol management
• Call attention to the link between cholesterol and arterial plaque buildup
• Motivate at-risk patients to take better care of their arteries

See how AstraZeneca is helping educate at-risk patients about atherosclerosis.